Health Care·Health Care Equipment·$4.0B
Irhythm Holdings Inc (IRTC) operates in the health care sector, focusing on innovative health care equipment. The company is known for its advanced cardiac monitoring solutions, which are increasingly important as the demand for remote health monitoring grows.
EPS
Earnings per share (EPS) is a key indicator of profitability and will show how well the company is managing costs and generating revenue.
Revenue
Revenue figures will provide insight into the company's sales performance and market demand for its products.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
3Q
EPS Beat Rate
63%
Avg EPS Surprise
+201.49%
Avg Stock Reaction
-0.09%
In Q4-2025, Irhythm surprised analysts with an EPS of $0.29, significantly higher than the expected $0.02. This strong performance led to a positive market reaction, with the stock rising 3.27% the following day.
Management Promises & Guidance
Analysts are cautiously optimistic about Irhythm's upcoming earnings, expecting a loss but with potential for better-than-expected results. The company has shown a tendency to beat estimates in the past, which could influence market reactions.
Bull Case
If Irhythm can deliver results significantly better than the consensus EPS of -$0.64, it may signal strong operational improvements and increased market demand.
Bear Case
Conversely, if the company fails to meet expectations, particularly in revenue, it could raise concerns about its growth trajectory and market competitiveness.
EPS
-$0.64Earnings per share (EPS) is a key indicator of profitability and will show how well the company is managing costs and generating revenue.
Revenue
$194MRevenue figures will provide insight into the company's sales performance and market demand for its products.
The print will turn on these two things.
Q1
Will the company achieve revenue of at least $194M?
This figure is crucial as it reflects market demand and the effectiveness of Irhythm's sales strategies.
Q2
Can Irhythm improve its EPS from the consensus estimate of -$0.64?
A better EPS would indicate improved profitability and operational efficiency, which are key to investor confidence.
Why consensus could be wrong
The Street may underestimate Irhythm's potential for revenue growth due to its innovative product offerings and expanding market presence.
Supporting Evidence
The company has a history of beating EPS estimates, which could indicate stronger operational performance.
Recent improvements in product adoption rates suggest a growing customer base.
The health care equipment sector is experiencing increased demand, which may benefit Irhythm.
Key Risk
If revenue significantly exceeds $194M, it could challenge the current negative sentiment.
Pre-commit to what would confirm each case.
The market is debating whether Irhythm can sustain its growth trajectory amid competitive pressures and operational challenges.
Bull Confirmed If
An EPS improvement to better than -$0.47 would confirm the bull case.
Bear Confirmed If
An EPS worse than -$0.90 would confirm the bear case.
Implied Move
±N/A
There is no available options market data to gauge investor sentiment ahead of the earnings report.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Irhythm beats expectations, history suggests a potential stock increase of around 0.01%, confirming a positive trend.
In-Line / Cautious
If results are in line with expectations, the stock may react cautiously as investors assess future guidance.
Miss
A miss could lead to a decline of approximately 0.26%, reflecting investor disappointment.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
VERIZON COMMUNICATIO
Apr 27, 2026